NEW TEST

Click for Pricing

# C5 Inhibitors Drug Monitoring Panel

3005961, C5 INH PAN

| | |
|---|---|
| Specimen Requirements: | |
| Patient Preparation: | |
| Collect: | Plain red. |
| Specimen Preparation: | Separate serum from cells ASAP or within 2 hours of collection. Transfer 2.0 mL serum to an ARUP standard transport tube and freeze immediately. (Min: 2.0 mL) |
| Transport Temperature: | CRITICAL FROZEN. Separate specimens must be submitted when multiple tests are ordered. |
| Unacceptable Conditions: | Specimens received refrigerated, ambient, lipemic specimens, or grossly hemolyzed specimens. Serum separator tubes. Specimens collected using calcium-binding anticoagulants (i.e., EDTA, ACD). |
| Remarks: | |
| Stability: | Refer to individual components. |
| Methodology: | Quantitative Turbidimetric/Quantitative Radial Immunodiffusion |
| Performed: | Tue, Fri |
| Reported: | 1-9 days |
| Note: | |
| CPT Codes: | 86160; 86161 x2; 86162 |
| New York DOH Approval Status: | This test is New York DOH approved. |

Interpretive Data:

| Component | Interpretation |
|---|---|
| Complement Activity, Total Turbidimetric | Low: 38.6 U/mL or less Normal: 38.7-89.9 U/mL High: 90.0 U/mL or greater |
| Complement C5, Functional | Low: 22.9 U/mL or less Low-Normal: 23.0-28.3 U/mL Normal: |

| | | |
|---|---|---|
| | 28.4 U/mL or greater | |
| Complement Activity, Alternative Pathway | This test is intended for screening of functional activity of the alternative pathway of the complement system. Abnormal test results can be due to hereditary absence or acquired functional defect in the activity of any of the individual components of the alternative pathway. | |
| C5 Inhibitors Drug Monitoring Pan Interp | Patients treated with C5 inhibitors may show decreased/absent activity in total complement functional assay (CH50), alternative pathway functional assay (AH50), and C5 functional assay with normal or elevated C5 protein concentrations. Normal CH50, AH50, or C5 functional activity with normal or elevated C5 protein concentrations indicate inadequate complement blockage. Serial measurements are recommended when monitoring treatment efficacy. Decreases in both C5 concentration and C5 functional activity suggests a secondary | |

| | | |
|---|---|---|
| | consumption process or C5 deficiency. Repeat testing using a new specimen is suggested if in vitro complement activation and consumption of components due to conditions of collection, transport, and/or handling is suspected. | |

Reference Interval:

| Test Number | Components | Reference Interval |
|---|---|---|
| | Complement Activity, Total Turbidimetric | 38.7-89.9 U/mL |
| | Complement Component 5 | 7-20 mg/dL |
| | Complement Activity, Alternative Pathway | 59 percent normal or greater |
| | Complement C5, Functional | 23.0 U/mL or greater |

HOTLINE NOTE: Refer to the Hotline Test Mix for interface build information.